{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T07:22:43Z","timestamp":1777447363483,"version":"3.51.4"},"reference-count":20,"publisher":"Harborside Press, LLC","issue":"12","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.6004\/jnccn.2025.7136","type":"journal-article","created":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:20Z","timestamp":1765979780000},"page":"574-575","source":"Crossref","is-referenced-by-count":1,"title":["Equal Access, Enduring Questions: How Race and Treatment Influence Survival in Advanced Prostate Cancer Among US Veterans"],"prefix":"10.6004","volume":"23","author":[{"given":"Shannon R.","family":"Stock","sequence":"first","affiliation":[{"name":"Department of Surgery, Durham VA Health Care System, Durham, NC"},{"name":"Department of Mathematics and Computer Science, College of the Holy Cross, Worcester, MA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephen J.","family":"Freedland","sequence":"additional","affiliation":[{"name":"Department of Surgery, Durham VA Health Care System, Durham, NC"},{"name":"Department of Urology, Cedars-Sinai Medical Center, Los Angeles, CA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"4047","reference":[{"key":"B1","series-title":"J Clin Oncol","first-page":"403","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi S","year":"2019","unstructured":"Halabi S, Dutta S, Tangen CM,  Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol 2019;37:403\u2013410."},{"key":"B2","series-title":"JAMA Netw Open","first-page":"e2144027","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system","volume":"5","author":"Yamoah K","year":"2022","unstructured":"Yamoah K, Lee KM, Awasthi S,  Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system. JAMA Netw Open 2022;5:e2144027."},{"key":"B3","series-title":"J Natl Compr Canc Netw","first-page":"507","article-title":"The impact of race on survival and treatment in Veterans treated for metastatic castration-resistant prostate cancer","volume":"12","author":"Candelieri-Surette D","year":"2025","unstructured":"Candelieri-Surette D, Cheranda N, Teerlink C,  The impact of race on survival and treatment in Veterans treated for metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw 2025;12:507\u2013515."},{"key":"B4","series-title":"Prostate Cancer Prostatic Dis","first-page":"461","article-title":"The impact of race on survival in metastatic prostate cancer: a systematic literature review","volume":"26","author":"Freedland SJ","year":"2023","unstructured":"Freedland SJ, Samjoo IA, Rosta E,  The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis 2023;26:461\u2013474."},{"key":"B5","series-title":"JAMA Netw Open","first-page":"e2142093","article-title":"Outcomes among African American and Non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar M","year":"2022","unstructured":"Marar M, Long Q, Mamtani R,  Outcomes among African American and Non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open 2022;5:e2142093."},{"key":"B6","series-title":"Clin Cancer Res","first-page":"320","article-title":"Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer","volume":"27","author":"Awasthi S","year":"2021","unstructured":"Awasthi S, Berglund A, Abraham-Miranda J,  Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clin Cancer Res 2021;27:320\u2013329."},{"key":"B7","series-title":"Genome Med","first-page":"92","article-title":"Prostate cancers with distinct transcriptional programs in Black and White men","volume":"16","author":"Kim M","year":"2024","unstructured":"Kim M, Tamukong P, Galvan GC,  Prostate cancers with distinct transcriptional programs in Black and White men. Genome Med 2024;16:92."},{"key":"B8","series-title":"JAMA Netw Open","first-page":"e2428444","article-title":"Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer","volume":"7","author":"La J","year":"2024","unstructured":"La J, Wang L, Corrigan JK,  Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer. JAMA Netw Open 2024;7:e2428444."},{"key":"B9","series-title":"Prostate Cancer Prostatic Dis","first-page":"756","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"27","author":"George DJ","year":"2024","unstructured":"George DJ, Ramaswamy K, Yang H,  Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2024;27:756\u2013764."},{"key":"B10","series-title":"Prostate Cancer Prostatic Dis","first-page":"776","article-title":"Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study","volume":"27","author":"Lee YHA","year":"2024","unstructured":"Lee YHA, Hui JMH, Leung CH,  Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis 2024;27:776\u2013782."},{"key":"B1","series-title":"J Clin Oncol","first-page":"403","article-title":"Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel","volume":"37","author":"Halabi S","year":"2019","unstructured":"Halabi S, Dutta S, Tangen CM,  Overall survival of Black and White men with metastatic castration-resistant prostate cancer treated with docetaxel. J Clin Oncol 2019;37:403\u2013410."},{"key":"B2","series-title":"JAMA Netw Open","first-page":"e2144027","article-title":"Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system","volume":"5","author":"Yamoah K","year":"2022","unstructured":"Yamoah K, Lee KM, Awasthi S,  Racial and ethnic disparities in prostate cancer outcomes in the Veterans Affairs health care system. JAMA Netw Open 2022;5:e2144027."},{"key":"B3","series-title":"J Natl Compr Canc Netw","first-page":"507","article-title":"The impact of race on survival and treatment in Veterans treated for metastatic castration-resistant prostate cancer","volume":"12","author":"Candelieri-Surette D","year":"2025","unstructured":"Candelieri-Surette D, Cheranda N, Teerlink C,  The impact of race on survival and treatment in Veterans treated for metastatic castration-resistant prostate cancer. J Natl Compr Canc Netw 2025;12:507\u2013515."},{"key":"B4","series-title":"Prostate Cancer Prostatic Dis","first-page":"461","article-title":"The impact of race on survival in metastatic prostate cancer: a systematic literature review","volume":"26","author":"Freedland SJ","year":"2023","unstructured":"Freedland SJ, Samjoo IA, Rosta E,  The impact of race on survival in metastatic prostate cancer: a systematic literature review. Prostate Cancer Prostatic Dis 2023;26:461\u2013474."},{"key":"B5","series-title":"JAMA Netw Open","first-page":"e2142093","article-title":"Outcomes among African American and Non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone","volume":"5","author":"Marar M","year":"2022","unstructured":"Marar M, Long Q, Mamtani R,  Outcomes among African American and Non-Hispanic White men with metastatic castration-resistant prostate cancer with first-line abiraterone. JAMA Netw Open 2022;5:e2142093."},{"key":"B6","series-title":"Clin Cancer Res","first-page":"320","article-title":"Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer","volume":"27","author":"Awasthi S","year":"2021","unstructured":"Awasthi S, Berglund A, Abraham-Miranda J,  Comparative genomics reveals distinct immune-oncologic pathways in African American men with prostate cancer. Clin Cancer Res 2021;27:320\u2013329."},{"key":"B7","series-title":"Genome Med","first-page":"92","article-title":"Prostate cancers with distinct transcriptional programs in Black and White men","volume":"16","author":"Kim M","year":"2024","unstructured":"Kim M, Tamukong P, Galvan GC,  Prostate cancers with distinct transcriptional programs in Black and White men. Genome Med 2024;16:92."},{"key":"B8","series-title":"JAMA Netw Open","first-page":"e2428444","article-title":"Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer","volume":"7","author":"La J","year":"2024","unstructured":"La J, Wang L, Corrigan JK,  Abiraterone or enzalutamide for patients with metastatic castration-resistant prostate cancer. JAMA Netw Open 2024;7:e2428444."},{"key":"B9","series-title":"Prostate Cancer Prostatic Dis","first-page":"756","article-title":"Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer","volume":"27","author":"George DJ","year":"2024","unstructured":"George DJ, Ramaswamy K, Yang H,  Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naive patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis 2024;27:756\u2013764."},{"key":"B10","series-title":"Prostate Cancer Prostatic Dis","first-page":"776","article-title":"Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study","volume":"27","author":"Lee YHA","year":"2024","unstructured":"Lee YHA, Hui JMH, Leung CH,  Major adverse cardiovascular events of enzalutamide versus abiraterone in prostate cancer: a retrospective cohort study. Prostate Cancer Prostatic Dis 2024;27:776\u2013782."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-p574.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-p574.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/23\/12\/article-p574.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,17]],"date-time":"2025-12-17T13:56:21Z","timestamp":1765979781000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/23\/12\/article-p574.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":20,"journal-issue":{"issue":"12"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2025.7136","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,12]]}}}